Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05632315 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

PMT for MDRO Decolonization

StatusCompleted
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial completed Primary and study completion dates changed from estimate of Aug 2026 to Aug 24, 2026 · Eligibility criteria expanded, about 20 words Show 2 more changesShow less
    • Primary and study completion dates changed from estimate of Aug 2026 to Aug 24, 2026
    • Eligibility criteria expanded, about 20 words
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 150 to confirmed 32 · Primary and study completion dates: May 2026 to Aug 2026 · Site details revised at 3 of 3 sitesv15 Show 3 more changesShow less
    • Enrollment target: estimated 150 to confirmed 32
    • Primary and study completion dates: May 2026 to Aug 2026
    • Site details revised at 3 of 3 sites
  3. Study sites: 2 to 3 Primary and study completion dates: Jan 2026 to May 2026v14 Show 1 more changeShow less
    • Primary and study completion dates: Jan 2026 to May 2026
  4. Study sites: 1 to 2v13
  5. Eligibility criteria shortened, about 1 wordv12 See this version in full on ClinicalTrials.gov ↗
Show 10 earlier versionsHide 10 earlier versions
  1. Start date changed from estimate of Jul 2024 to Aug 19, 2024 Secondary endpoints: details revised at 8 of 13 entries · Eligibility criteria expanded, about 3 wordsv11 Show 2 more changesShow less
    • Secondary endpoints: details revised at 8 of 13 entries
    • Eligibility criteria expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  2. Trial status: Not Yet Recruiting to Recruiting Start date: Jun 2024 to Jul 2024 · Site details revisedv10 Show 2 more changesShow less
    • Start date: Jun 2024 to Jul 2024
    • Site details revised
  3. Start date: Mar 2024 to Jun 2024v9
  4. Re-verified, no change to tracked fieldsv8
  5. Start date: Jan 2024 to Mar 2024v7
  6. Start date: Dec 2023 to Jan 2024v6
  7. Start date: Sep 2023 to Dec 2023v5
  8. Start date: Jun 2023 to Sep 2023v4
  9. Start date: Apr 2023 to Jun 2023v3
  10. Start date: Jan 2023 to Apr 2023 Primary endpoints: 4 to 5 · Eligibility criteria expanded, about 108 words · Secondary endpoints: 9 to 13 · 1 morev2 Show 4 more changesShow less
    • Primary endpoints: 4 to 5
    • Eligibility criteria expanded, about 108 words
    • Secondary endpoints: 9 to 13
    • Study arms: 20 to 24

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, open label, comparative Phase II trial being conducted to determine whether fecal microbiota transplant using Penn Microbiome Therapy (PMT) products helps standard therapy eradicate antibiotic-resistant bacteria.
Trial Details
NCT Number NCT05632315
Lead Sponsor University of Pennsylvania
Conditions Multidrug Resistant Bacterial Infection, Enterobacteriaceae Infections, Pseudomonas Aeruginosa, VRE Infection, Methicillin-resistant Staphylococcus Aureus
Enrollment 32 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov